Granules India Limited · NSE:GRANULES
Granules India — Investor Presentation (2017)
14 slides from Granules India's investor presentation, 2017
Slide 1: Investor Presentation: Q1FY18
Investor Presentation: Q1FY18
Slide 2: What we stand for: Propelling for enduring growth
“What we stand for” Propelling for enduring growth Key Levers : Technical – Portfolio - IP – Regulatory (Amalgamation of Core and Emerging Business value streams) 1 2 3 4 5 Our key stake holders) Economies of scale and with Marque customers (Long term relationship (Market Leadership) relationships (
Slide 3: Company Snapshot
Company Snapshot Present across the entire pharmaceutical manufacturing Listing information : NSE value chain from active pharmaceutical ingredients (API) Market Cap (INR mn) as on June’17 30,522 to pharmaceutical formulation intermediates (PFI) to Outstanding Equity Shares (mn) 228.80 finished do
Slide 4: Core Business Model
Core Business Model Vertically integrated across the entire value chain from active pharmaceutical ingredients (API) to pharmaceutical formulation intermediates (PFI) to finished dosages (FD) manufacturing of “High Volume Products” Strong presence in ‘first line of defense’ products such as such
Slide 5: Initiatives for Future Growth
Initiatives for Future Growth New API Division Auctus Acquisition – High-potential New API business. Significant saving; capacities with regulatory approvals for Granules growth strategy. USFDA approved multipurpose API manufacturing facility in Vizag and an intermediate manufacturing facility
Slide 6: Granules OmniChem (CRAMS Business)
Granules OmniChem (CRAMS Business) Foray into Contract Research And Manufacturing Services Set up in July 2011 as a 50-50 JV company with Belgium based Omnichem, a part of the Ajinomoto Group. The JV has set up a facility in Vizag SEZ for manufacturing of high-value APIs for Innovators and Brand
Slide 7: Group Structure and Manufacturing Capabilities
Group Structure and Manufacturing Capabilities Incorporated in 1991, this is the only listed entity in the group, with 4 plants located in Granules India Hyderabad (Jeedimetla, Bonthapally and Gagillapur) and 1 in Vizag Pharma City Granules USA Inc. 100% subsidiary, for front-end marketing in the U.
Slide 8: Consolidated Revenue Break-up for Q1FY18
Consolidated Revenue Break-up for Q1FY18 V PRODUCTION DETAILS E Q1FY17 Q1FY18 R 5,033 T 4,627 I C FD; 39% API; 37% 3,099 A 2,780 L 1,543 1,729 W I PFI; 24% S E API in MT PFI in MT FD in Mn ROW G Latin 4% M E America O MCB; 2% O 12% L OTHERS; GUAI; 5% 14% G E R North C A America U PARA; 34% P India 3
Slide 9: Comparison of yearly Revenue Break-up
Comparison of yearly Revenue Break-up FY17 MOLECULE WISE FY'16 FY'17 40% 34% 30% 26% V FD API 38% 38% E 14%14% 12%13% R 6% 5% T PFI 2% 3% 24% I PARA MF IBU GUAI MCB OTHERS C A L FY16 GEOGRAPHY WISE 42% 39% W FY'16 FY'17 I S FD 25% 33% API 22% 21% 18% E 39% 12% 10% 6% 5% PFI 28% North Europe India La
Slide 10: Financial Overview – Trends
Financial Overview – Trends 14,353 13,829 PAT EBITDA Revenue 12,937 10,959 7,644 6,540 4,752 2,815 3,088 2,130 1,626 1,645 871 909 1,230 805 752 209 576 300 326 FY 11 FY 12 FY 13 FY 14 FY 15 FY 16 FY 17 21.5% PAT Margin (%) EBITDA Margin (%) 20.4% 16.5% 14.8% 12.1% 12.3% 11.4% 11.5% 8.9% 6.9% 7.0% 4
Slide 11: Consolidated Financial Overview
Consolidated Financial Overview Consolidated Financial Snapshot (INR Mn) 27.2% FY16 FY17 23.8% 22.5% 21.0% Income from Operation 13,829 14,353 FY 16 Material Cost 7,250 6,796 FY 17 Other Operating Exp. 3,816 4,568 Other Income 52 99 EBITDA 2,815 3,088 ROCE (%) ROE (%) EBITDA Margin (%) 20.4% 21.5% E
Slide 12: Financial Snapshots of JVs
Financial Snapshots of JVs Granules Omnichem 28% 20% FY 16 FY 17 2,003 12% FY 16 FY 17 391 249 143 40 -72% (102) PAT EBITDA Revenue PAT Margin (%) EBITDA Margin (%) Granules Biocause FY 16 FY 17 2,200 15.2% 1,701 7.6% 11.2% 3.8% 334 246 65 129 FY 16 FY 17 PAT EBITDA Revenue PAT Margin (%) EBITDA Mar
Slide 13: Core Management Team
Core Management Team Mr. C. Krishna Prasad - Chairman and Managing Director Mr. Prasad is the Founder of Granules and has three decades of experience in the pharmaceutical industry. In 1984, he set up a Paracetamol manufacturing facility, focused on capital and process efficiency. Pharmaceutical For
Slide 14: Disclaimer
Disclaimer The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any i